Report of a preliminary discontinued double-blind, randomized, placebo-controlled trial of the anti-tnf-α chimeric monoclonal antibody infliximab in complex regional pain syndrome

Pain Practice

Volumn 13, Issue 8, 2013, Pages 633-640

  Dirckx, Maaike ^a   Groeneweg, George ^a   Wesseldijk, Feikje ^a   Stronks, Dirk L ^a   Huygen, Frank J P M ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Anti inflammatory agents; Anti tumor necrosis factor; Complex regional pain syndromes; Infliximab; TNF alpha

Indexed keywords

GAMMA INTERFERON INDUCIBLE PROTEIN 10; INFLIXIMAB; INTERLEUKIN 8; PLACEBO; RANTES; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; BLISTER; BLOOD PRESSURE; CLINICAL ARTICLE; COMPLEX REGIONAL PAIN SYNDROME; CONSTIPATION; CONTROLLED STUDY; DIPLOPIA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG INDUCED HEADACHE; DRUG SAFETY; FEMALE; HEALTH STATUS; HERPES SIMPLEX; HUMAN; INFLAMMATION; INFLUENZA; MALAISE; MALE; NAUSEA; PAIN ASSESSMENT; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SHORT FORM 36; SIDE EFFECT; SYMPTOM CHECKLIST 90; VISUAL ANALOG SCALE;

ANTI-INFLAMMATORY AGENTS; ANTI-TUMOR NECROSIS FACTOR; COMPLEX REGIONAL PAIN SYNDROMES; INFLIXIMAB; TNF-ALPHA;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; COMPLEX REGIONAL PAIN SYNDROMES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; PAIN; QUALITY OF LIFE; RANGE OF MOTION, ARTICULAR; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84887411974     PISSN: 15307085     EISSN: 15332500     Source Type: Journal    
DOI: 10.1111/papr.12078     Document Type: Article

References (23)

1. Stanton-Hicks M, Janig W, Hassenbusch S, Haddox JD, Boas R, Wilson P. Reflex sympathetic dystrophy: changing concepts and taxonomy. Pain. 1995;63:127-133.
2. de Mos M, de Bruijn AG, Huygen FJ, Dieleman JP, Stricker BH, Sturkenboom MC. The incidence of complex regional pain syndrome: a population-based study. Pain. 2007;129:12-20.
3. Schwartzman RJ, Popescu A. Reflex sympathetic dystrophy. Curr Rheumatol Rep. 2002;4:165-169.
4. Wesseldijk F, Fekkes D, Huygen FJ, Bogaerts-Taal E, Zijlstra FJ. Increased plasma serotonin in complex regional pain syndrome type 1. Anesth Analg. 2008;106:1862-1867.
5. Wesseldijk F, Fekkes D, Huygen FJ, van de Heide-Mulder M, Zijlstra FJ. Increased plasma glutamate, glycine, and arginine levels in complex regional pain syndrome type 1. Acta Anaesthesiol Scand. 2008;52:688-694.
6. Wesseldijk F, Huygen FJ, Heijmans-Antonissen C, Niehof SP, Zijlstra FJ. Six years follow-up of the levels of TNF-alpha and IL-6 in patients with complex regional pain syndrome type 1. Mediators Inflamm. 2008;2008:469439.
7. Wesseldijk F, Huygen FJ, Heijmans-Antonissen C, Niehof SP, Zijlstra FJ. Tumor necrosis factor-alpha and interleukin-6 are not correlated with the characteristics of Complex Regional Pain Syndrome type 1 in 66 patients. Eur J Pain. 2008;12:716-721.
8. Uceyler N, Eberle T, Rolke R, Birklein F, Sommer C. Differential expression patterns of cytokines in complex regional pain syndrome. Pain. 2007;132:195-205.
9. Huygen FJ, De Bruijn AG, De Bruin MT, Groeneweg JG, Klein J, Zijlstra FJ. Evidence for local inflammation in complex regional pain syndrome type 1. Mediators Inflamm. 2002;11:47-51.
10. Huygen FJ, de Bruijn AG, Klein J, Zijlstra FJ. Neuroimmune alterations in the complex regional pain syndrome. Eur J Pharmacol. 2001;429:101-113.
11. Huygen FJ, Niehof S, Zijlstra FJ, van Hagen PM, van Daele PL. Successful treatment of CRPS 1 with anti-TNF. J Pain Symptom Manage. 2004;27:101-103.
12. Choo-Kang BS, Hutchison S, Nickdel MB, et al. TNF-blocking therapies: an alternative mode of action? Trends Immunol. 2005;26:518-522.
13. Bruehl S, Harden RN, Galer BS, et al. External validation of IASP diagnostic criteria for Complex Regional Pain Syndrome and proposed research diagnostic criteria. International Association for the Study of Pain. Pain. 1999;81:147-154.
14. Oerlemans HM, Goris RJ, Oostendorp RA. Impairment level sumscore in reflex sympathetic dystrophy of one extremity. Arch Phys Med Rehabil. 1998;79:979-990.
15. Vanderiet K, Adriaensen H, Carton H, Vertommen H. The McGill Pain Questionnaire constructed for the dutch language (MPQ-DV). Preliminary data concerning reliabilty and validity. Pain. 1987;30:395-408.
16. Heijmans-Antonissen C, Wesseldijk F, Munnikes RJ, et al. Multiplex bead array assay for detection of 25 soluble cytokines in blister fluid of patients with complex regional pain syndrome type 1. Mediators Inflamm. 2006;2006:28398.
17. Huygen FJ, Niehof SJ, Klein J, Zijlstra FJ. Computer compiled skin videothermography is a high sensitive quality tool in the diagnosis and monitoring of complex regional pain syndrome type I. Eur J Appl Physiol. 2004;91:516-524.
18. Groeneweg JG, Huygen FJ, Heijmans-Antonissen C, Niehof S, Zijlstra FJ. Increased endothelin-1 and diminished nitric oxide levels in blister fluids of patients with intermediate cold type complex regional pain syndrome type 1. BMC Musculoskelet Disord. 2006;7:91-99.
19. Groeneweg G, Huygen FJ, Coderre TJ, Zijlstra FJ. Regulation of peripheral blood flow in Complex Regional Pain Syndrome: clinical implication for symptomatic relief and pain management. BMC Musculoskelet Disord. 2009;10:116.
20. Albrecht PJ, Hines S, Eisenberg E, et al. Pathologic alterations of cutaneous innervation and vasculature in affected limbs from patients with complex regional pain syndrome. Pain. 2006;120:244-266.
21. Hulsman NM, Geertzen JH, Dijkstra PU, van den Dungen JJ, den Dunnen WF. Myopathy in CRPS-I: Disuse or neurogenic? Eur J Pain. 2009;13:731-736.
22. Oaklander AL. RSD/CRPS: the end of the beginning. Pain. 2008;139:239-240.
23. van der Laan L, Veldman PH, Goris RJ. Severe complications of reflex sympathetic dystrophy: infection, ulcers, chronic edema, dystonia, and myoclonus. Arch Phys Med Rehabil. 1998;79:424-429.